BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26637226)

  • 21. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [High aldehyde dehydrogenase 1A1 (ALDH1A1) expression correlated with risk of lymph node metastasis in papillary thyroid carcinoma].
    Yue C; Zhao X; Tian C; Jin Y; Liu H
    Zhonghua Bing Li Xue Za Zhi; 2015 Jul; 44(7):490-4. PubMed ID: 26705040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CHK2 Promotes Anoikis and is Associated with the Progression of Papillary Thyroid Cancer.
    Zhao W; Chen S; Hou X; Chen G; Zhao Y
    Cell Physiol Biochem; 2018; 45(4):1590-1602. PubMed ID: 29486482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Downregulation of serum DKK-1 predicts poor prognosis in patients with papillary thyroid cancer.
    Zhao YP; Wang W; Wang XH; Xu Y; Wang Y; Dong ZF; Zhang JJ
    Genet Mol Res; 2015 Dec; 14(4):18886-94. PubMed ID: 26782539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered expression of estrogen receptor β2 is associated with different biological markers and clinicopathological factors in papillary thyroid cancer.
    Dong W; Li J; Zhang H; Huang Y; He L; Wang Z; Shan Z; Teng W
    Int J Clin Exp Pathol; 2015; 8(6):7149-56. PubMed ID: 26261608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the diagnostic value of emerin and CD56 in papillary thyroid carcinoma - an immunohistochemical study.
    Abdou AG; Abdelwahed M; Said A; Taie DM; Fahmy S
    J Immunoassay Immunochem; 2018; 39(5):521-537. PubMed ID: 30188764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of long non-coding RNA NR_036575.1 contributes to the proliferation and migration of papillary thyroid cancer.
    Sun W; Lan X; Wang Z; Dong W; He L; Zhang T; Zhang H
    Med Oncol; 2016 Sep; 33(9):102. PubMed ID: 27510368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical levels of matrix metalloproteinase-2 and CD44 variant 6 protein in the diagnosis and lateral cervical lymph node metastasis of papillary thyroid carcinoma.
    Wu G; Zhou Y; Li T; Guo J; Zhou Z
    J Int Med Res; 2013 Jun; 41(3):816-24. PubMed ID: 23685894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
    Abouhashem NS; Talaat SM
    Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of chemokine CXC motif ligand 12 as a novel diagnostic marker in preoperative fine-needle aspiration biopsy for papillary thyroid carcinoma.
    Jung YY; Park IA; Kim MA; Min HS; Won JK; Ryu HS
    Acta Cytol; 2013; 57(5):447-54. PubMed ID: 24021782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CHI3L1 overexpression is associated with metastasis and is an indicator of poor prognosis in papillary thyroid carcinoma.
    Luo D; Chen H; Lu P; Li X; Long M; Peng X; Huang M; Huang K; Lin S; Tan L; Zhu Y; Chen Z; Ouyang N; Li H
    Cancer Biomark; 2017; 18(3):273-284. PubMed ID: 28009325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of survivin expression and its prognostic value in papillary thyroid carcinoma.
    Selemetjev S; Dencic TI; Marecko I; Jankovic J; Paunovic I; Savin S; Cvejic D
    Pathol Res Pract; 2014 Jan; 210(1):30-4. PubMed ID: 24199968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Downregulation of miR‑486‑5p in papillary thyroid carcinoma tissue: A study based on microarray and miRNA sequencing.
    Wen DY; Pan DH; Lin P; Mo QY; Wei YP; Luo YH; Chen G; He Y; Chen JQ; Yang H
    Mol Med Rep; 2018 Sep; 18(3):2631-2642. PubMed ID: 30015845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Relationship between activated STAT3 protein and epithelial-mesenchymal transition in papillary thyroid carcinoma].
    Zhang Z; Bai Y; Li P; Zhao J; Wang Y; Sun L; Tang J
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 Nov; 27(22):1265-8. PubMed ID: 24616987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genome-Wide Expression Screening Discloses Long Noncoding RNAs Involved in Thyroid Carcinogenesis.
    Liyanarachchi S; Li W; Yan P; Bundschuh R; Brock P; Senter L; Ringel MD; de la Chapelle A; He H
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4005-4013. PubMed ID: 27459529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of TGF-β1, SNAI1 and MMP-9 is associated with lymph node metastasis in papillary thyroid carcinoma.
    Wang N; Jiang R; Yang JY; Tang C; Yang L; Xu M; Jiang QF; Liu ZM
    J Mol Histol; 2014 Aug; 45(4):391-9. PubMed ID: 24276590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IL-4, IL-10 and high sensitivity-CRP as potential serum biomarkers of persistent/recurrent disease in papillary thyroid carcinoma with/without Hashimoto's thyroiditis.
    Stanciu AE; Serdarevic N; Hurduc AE; Stanciu MM
    Scand J Clin Lab Invest; 2015 Nov; 75(7):539-48. PubMed ID: 26305420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
    Išić Denčić T; Bartolome A; Šelemetjev S; Đorić I; Tatić S; Živaljević V; Cvejić D
    Exp Mol Pathol; 2018 Oct; 105(2):181-189. PubMed ID: 30077672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyroglobulin in washout fluid from lymph node fine-needle aspiration biopsy in papillary thyroid cancer: large-scale validation of the cutoff value to determine malignancy and evaluation of discrepant results.
    Moon JH; Kim YI; Lim JA; Choi HS; Cho SW; Kim KW; Park HJ; Paeng JC; Park YJ; Yi KH; Park DJ; Kim SE; Chung JK
    J Clin Endocrinol Metab; 2013 Mar; 98(3):1061-8. PubMed ID: 23393171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CIP2A is a poor prognostic factor and can be a diagnostic marker in papillary thyroid carcinoma.
    Chao TT; Maa HC; Wang CY; Pei D; Liang YJ; Yang YF; Chou SJ; Chen YL
    APMIS; 2016 Dec; 124(12):1031-1037. PubMed ID: 27649840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.